Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Norris Perne & French LLP MI

Norris Perne & French LLP MI reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,765 shares of the medical research company’s stock after selling 290 shares during the period. Thermo Fisher Scientific comprises approximately 1.5% of Norris Perne & French LLP MI’s holdings, making the stock its 26th biggest position. Norris Perne & French LLP MI’s holdings in Thermo Fisher Scientific were worth $22,123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. Mission Wealth Management LP raised its holdings in shares of Thermo Fisher Scientific by 8.6% during the first quarter. Mission Wealth Management LP now owns 4,326 shares of the medical research company’s stock valued at $2,514,000 after acquiring an additional 342 shares during the period. Avior Wealth Management LLC grew its position in Thermo Fisher Scientific by 7.9% in the first quarter. Avior Wealth Management LLC now owns 4,251 shares of the medical research company’s stock valued at $2,471,000 after acquiring an additional 313 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Thermo Fisher Scientific by 2.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,668 shares of the medical research company’s stock worth $49,366,000 after acquiring an additional 1,754 shares during the last quarter. 1834 Investment Advisors Co. grew its position in shares of Thermo Fisher Scientific by 10.0% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,809 shares of the medical research company’s stock worth $1,051,000 after buying an additional 164 shares during the period. Finally, Connecticut Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 1.1% during the first quarter. Connecticut Wealth Management LLC now owns 4,842 shares of the medical research company’s stock valued at $2,814,000 after purchasing an additional 54 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $546.55 on Friday. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $208.78 billion, a PE ratio of 34.27, a P/E/G ratio of 3.64 and a beta of 0.77. The business has a 50 day moving average of $600.36 and a 200-day moving average of $583.31. Thermo Fisher Scientific Inc. has a 12-month low of $433.15 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the firm earned $5.69 EPS. The firm’s quarterly revenue was up .2% on a year-over-year basis. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Stephens began coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target for the company. Bank of America boosted their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Bernstein Bank raised their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Insider Activity

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,300 shares of company stock valued at $6,831,268 over the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.